Experimental and clinical pharmacology of fentiazac, a new, non-steroidal anti-inflammatory agent

Publisher Website
Google Scholar
Abstract
SummaryAnimal studies using standard in vitro and in vivo techniques have shown that fentiazac, a novel alkanoic acid derivative, has marked analgesic, anti-inflammatory and antipyretic activity. In common with some other anti-inflammatory agents, it also has platelet anti-aggregation activity. Fentiazac is well absorbed after oral and rectal administration and the drug has been widely studied in man in doses ranging from 600 mg to 900 mg per day orally and from 200 mg to 400 mg per day given rectally. The results of clinical trials involving 712 patients are reviewed and indicate that fentiazac is an effective and well tolerated agent which compares favourably with other such agents used in the treatment of rheumatic disorders and other painful conditions.